Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma

Targeted therapy effective for patients with advanced bladder cancer and specific gene mutationsПодробнее

Discussion on Trial Investigating Erdafitinib in Patients With Urothelial CancerПодробнее

Erdafitinib for FGFR-mutated urothelial carcinomaПодробнее

Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancerПодробнее

An Overview of Targeted FGFR3 Therapy in Bladder Cancer With Dr. Siefker-RadtkeПодробнее

An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinomaПодробнее

Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial CarcinomaПодробнее

Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder CancerПодробнее

Dr. Siefker-Radtke on the Treatment of FGFR-Altered Bladder CancerПодробнее

ESMO Dr. Siefker-RadtkeПодробнее

Arlene Siefker-Radtke, MD, regarding the EV-201 Cohort 2 study & clinical implications for patientsПодробнее

Dr. Arlene O. Siefker-Radtke on Neoadjuvant Chemotherapy Plus Surgery in Bladder CancerПодробнее

Arlene Siefker-Radtke, MD, discusses some of the antibody drug conjugates currently in developmentПодробнее

Dr. Iyer on TRAEs With Erdafitinib in Urothelial CancerПодробнее

Phase 3 THOR Study Results: Erdafitinib vs. Chemotherapy in Advanced Urothelial Cancer | CRSF 2024Подробнее

New emerging treatment options and targeted therapies for bladder cancerПодробнее

Arlene Siefker-Radtke, ESMO 2019 - KEYNOTE-866 Phase III trial in bladder cancerПодробнее

Erdafitinib for bladder cancer: more to come following FDA approvalПодробнее